3-[1-(5-Methoxy-1-methyl-1H-indol-3-yl)-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid

ID: ALA104813

Chembl Id: CHEMBL104813

PubChem CID: 44336147

Max Phase: Preclinical

Molecular Formula: C20H16N2O4

Molecular Weight: 348.36

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(C(=O)O)cc31)cn2C

Standard InChI:  InChI=1S/C20H16N2O4/c1-22-10-12(14-9-13(26-2)4-6-18(14)22)8-16-15-7-11(20(24)25)3-5-17(15)21-19(16)23/h3-10H,1-2H3,(H,21,23)(H,24,25)/b16-8-

Standard InChI Key:  FCIIDEHWDIRWHN-PXNMLYILSA-N

Associated Targets(Human)

SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FCER2 Tchem Immunoglobulin epsilon Fc receptor (92 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Syk Tyrosine-protein kinase SYK (71 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 348.36Molecular Weight (Monoisotopic): 348.1110AlogP: 3.38#Rotatable Bonds: 3
Polar Surface Area: 80.56Molecular Species: ACIDHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 4.07CX Basic pKa: CX LogP: 3.09CX LogD: -0.03
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.71Np Likeness Score: -0.63

References

1. Lai JY, Cox PJ, Patel R, Sadiq S, Aldous DJ, Thurairatnam S, Smith K, Wheeler D, Jagpal S, Parveen S, Fenton G, Harrison TK, McCarthy C, Bamborough P..  (2003)  Potent small molecule inhibitors of spleen tyrosine kinase (Syk).,  13  (18): [PMID:12941345] [10.1016/s0960-894x(03)00658-9]
2. Xie HZ, Li LL, Ren JX, Zou J, Yang L, Wei YQ, Yang SY..  (2009)  Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.,  19  (7): [PMID:19254842] [10.1016/j.bmcl.2009.02.049]
3. Singh R, Masuda ES, Payan DG..  (2012)  Discovery and development of spleen tyrosine kinase (SYK) inhibitors.,  55  (8): [PMID:22257213] [10.1021/jm201271b]

Source